Notch signaling pathway in ovarian cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 564-566

  Rose, Stephen L ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

Developmental therapeutics; Notch; Ovarian cancer

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; GAMMA SECRETASE INHIBITOR; NOTCH RECEPTOR; NOTCH1 RECEPTOR; NOTCH3 RECEPTOR;

ANGIOGENESIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURGERY; COLON CANCER; GENE EXPRESSION; HUMAN; METASTASIS; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; REVIEW; SIGNAL TRANSDUCTION;

FEMALE; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, NOTCH; SIGNAL TRANSDUCTION;

EID: 67651039809     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a12ed2     Document Type: Review

References (33)

1. Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354:34-43.
2. Radtke F, Raj K. The role of Notch in tumorigenesis: oncogene or tumour suppressor? Nat Rev Cancer. 2003;3:756-767.
3. Brou C, Logeat F, Gupta N, et al. A novel proteolytic cleavage involved in Notch signaling: the role of the disintegrin-metalloprotease TACE. Mol Cell. 2000;5:207-216.
4. Mumm JS, Schroeter EH, Saxena MT, et al. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch. Mol Cell. 2000;5:197-206.
5. Artavanis-Tsakonas S, Rand MD, Lake RJ. Notch signaling: cell fate control and signal integration in development. Science. 1999;284: 770-776.
6. Klinakis A, Szabolcs M, Politi K, et al. Myc is a Notch1 transcriptional target and a requisite for Notch1-induced mammary tumorigenesis in mice. Proc Natl Acad Sci U S A. 2006;103:9262-9267.
7. Rangarajan A, Talora C, Okuyama R, et al. Notch signaling is a direct determinant of keratinocyte growth arrest and entry into differentiation. EMBO J. 2001;20:3427-3436.
8. Ronchini C, Capobianco AJ. Induction of cyclin D1 transcription and CDK2 activity by Notch (ic): Implication for cell cycle disruption in transformation by Notch (ic). Mol Cell Biol. 2001;21:5925-5934.
9. Weng AP, Millholland JM, Yashiro-Ohtani Y, et al. c-Myc is an important direct target of Notch1 in T-cell acute lymphoblastic leukemia/lymphoma. Genes Dev. 2006;20:2096-2109.
10. Wang Z, Zhang Y, Li Y, et al. Down-regulation of Notch-1 contributes to cell growth inhibition and apoptosis in pancreatic cancer cells. Mol Cancer Ther. 2006;5:483-493.
11. Reedijk M, Odorcic S, Chang L, et al. High-level coexpression of JAGI and NOTCHI is observed in human breast cancer and is associated with poor overall survival. Cancer Res. 2005;65:8530-8537.
12. Zagouras P, Stifani S, Blaumueller CM, et al. Alterations in Notch signaling in neoplastic lesions of the human cervix. Proc Natl Acad Sci U S A. 1995;92:6414-6418.
13. Sjolund J, Johansson M, Manna S, et al. Suppression of renal cell carcinoma growth by inhibition of Notch signaling in vitro and in vivo. J Clin Invest. 2008;118:217-228.
14. Ellisen LW, Bird J, West DC, et al. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell. 1991;66:649-661.
15. Wang Z, Zhang Y, Banerjee S, et al. Notch-1 down-regulation by curcumin is associated with the inhibition of cell growth and the induction of apoptosis in pancreatic cancer cells. Cancer. 2006;106: 2503-2513.
16. Wang Z, Zhang Y, Banerjee S, et al. Inhibition of nuclear factor kappab activity by genistein is mediated via Notch-1 signaling pathway in pancreatic cancer cells. Int J Cancer. 2006;118:1930-1936.
17. Wang Z, Banerjee S, Li Y, et al. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res. 2006;66:2778-2784.
18. Kunnimalaiyaan M, Chen H. Tumor suppressor role of Notch-1 signaling in neuroendocrine tumors. Oncologist. 2007;12:535-542.
19. Kunnimalaiyaan M, Traeger K, Chen H. Conservation of the Notch1 signaling pathway in gastrointestinal carcinoid cells. Am J Physiol Gastrointest Liver Physiol. 2005;289:G636-G642.
20. Kunnimalaiyaan M, Vaccaro AM, Ndiaye MA, et al. Overexpression of the NOTCHI intracellular domain inhibits cell proliferation and alters the neuroendocrine phenotype of medullary thyroid cancer cells. J Biol Chem. 2006;281:39819-39830.
21. Cancer Facts and Figures 2008. Atlanta, GA: American Cancer Society; 2008.
22. Lu KH, Patterson AP, Wang L, et al. Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res. 2004;10:3291-3300.
23. Euer NI, Kaul S, Deissler H, et al. Identification of L1CAM, Jagged2 and Neuromedin U as ovarian cancer-associated antigens. Oncol Rep. 2005;13:375-387.
24. Park JT, Li M, Nakayama K, et al. Notch3 gene amplification in ovarian cancer. Cancer Res. 2006;66:6312-6318.
25. Choi JH, Park JT, Davidson B, et al. Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion. Cancer Res. 2008;68:5716-5723.
26. Hopfer O, Zwahlen D, Fey MF, et al. The Notch pathway in ovarian carcinomas and adenomas. Br J Cancer. 2005;93:709-718.
27. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2007; 25:5165-5171.
28. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
29. Miles D CA, Romieu G, Dirix L, et al. Randomized, double-blind, placebo-controlled, phase III study of bevacizumab with docetaxel or docetaxel with placebo as first-line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO [meeting abstracts]. J Clin Oncol. 2008;26:LBA1011.
30. Lu C, Bonome T, Li Y, et al. Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res. 2007;67:1757-1768.
31. Kimura K, Satoh K, Kanno A, et al. Activation of Notch signaling in tumorigenesis of experimental pancreatic cancer induced by dimethylbenzanthracene in mice. Cancer Sci. 2007;98:155-162.
32. Curry CL, Reed LL, Golde TE, et al. Gamma secretase inhibitor blocks Notch activation and induces apoptosis in Kaposi's sarcoma tumor cells. Oncogene. 2005;24:6333-6344.
33. Paris D, Quadros A, Patel N, et al. Inhibition of angiogenesis and tumor growth by beta and gamma-secretase inhibitors. Eur J Pharmacol. 2005;514:1-15.